Top

Published in:

01-12-2024 | Transurethral Prostate Resection | Original Article

Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience

Authors: Waseem Tayeb, Raed A. Azhar, Mohnna Subahi, Sameer Munshi, Abdulrahman Qarni, Abdulaziz Bakhsh, Majid Sejiny, Turkey Almohaisen, Adel Alammari, Mohamed A. Elkoushy

Published in: World Journal of Urology | Issue 1/2024

Abstract

Purpose

To compare the efficacy of Rezūm with a matched cohort of patients undergoing transurethral resection of the prostate (TURP) for catheter-dependent urine retention secondary to benign prostate hyperplasia (BPH).

Methods

A retrospective review was performed for consecutive catheter-dependent patients who underwent Rezūm for BPH. Patients were matched and compared with a similar cohort undergoing TURP, using non-inferiority analysis on propensity score-matched patient pairs. Patients were followed up at 1, 3, 6 and 12 months by international prostate symptoms score (IPSS), quality of life (QoL) index, peak flow rate (Qmax) and postvoid residual urine (PVR).

Results

Eighty-one patients undergoing Rezūm were compared with equal number of matched patients who undergoing TURP. Patients undergoing Rezūm experienced significantly shorter operation time (25.5 ± 8.7 vs. 103.4 ± 12.6 min; p < 0.001), lower intraoperative bleeding (2.4% vs. 20.7%, p < 0.001), shorter hospital stay (1.2 ± 0.9 vs. 2.4 ± 1.3 d, p < 0.001) and longer catheter time (12.6 ± 6.0 vs. 2.3 ± 1.2 d, p < 0.001), with no need for transfusion. Successful postoperative voiding was comparable between both arms (90.2% vs. 92.7%, p = 0.78), respectively. Despite patients undergoing TURP had significantly better voiding outcomes after 1 and 3 months, both groups were comparable after six and 12 months in terms of mean IPSS (11.1 ± 6.4 vs. 10.8 ± 3.4, p = 0.71), QoL indices (2.4 ± 1.6 vs. 2.1 ± 2.3, p = 0.33) and Qmax (22.0 ± 7.7 v. 19.8 ± 6.9 ml/sec, p = 0.06).

Conclusion

This study supports the safety and efficacy of Rezūm in the management of catheter-dependent patients secondary to BPH, with comparable functional outcomes to TURP. Until a randomized clinical comparison is available, long-term data are crucially recommended to compare the recurrence and reoperation rates.

Chan DB, Ross CP, Dubowitch EP et al (2015) Predicting acute urine retention in patients with elevated postvoid residuals. Curr Urol 8(2):79–83. https://doi.org/10.1159/000365694CrossRef

Muruganandham K, Dubey D, Kapoor R (2007) Acute urinary retention in benign prostatic hyperplasia: risk factors and current management. Indian J Urol 23(4):347–353. https://doi.org/10.4103/0970-1591.35050CrossRefPubMedPubMedCentral

Elkoushy MA, Elshal AM, Elhilali MM (2015) Changing patients’ profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: a single-centre perspective. Can Urol Assoc 9(11–12):372–378. https://doi.org/10.5489/cuaj.3066CrossRef

Elshal AM, Elmansy HM, Elhilali MM (2013) Transurethral laser surgery for benign prostate hyperplasia in octogenarians: safety and outcomes. Urology 81(3):634–639. https://doi.org/10.1016/j.urology.2012.11.042CrossRefPubMed

Rassweiler J, Teber D, Kuntz R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50:969. https://doi.org/10.1016/j.eururo.2005.12.042CrossRefPubMed

Cindolo L, Morselli S, Campobasso D, et al (2023) One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort. Minerva Urol Nephrol 75:203–9. https://doi.org/10.23736/S2724-6051.22.05080-7

Nguyen D-D, Li T, Ferreira R et al (2023) Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: a review of Aquablation, Rezūm, and transperineal laser prostate ablation. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-023-00669-zCrossRefPubMedPubMedCentral

Manfredi C, Arcaniolo D, Spatafora P et al (2022) Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol 74(4):389–399. https://doi.org/10.23736/S2724-6051.21.04530-4CrossRefPubMed

Eredics K, Wehrberger C, Henning A et al (2022) Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency. Prostate Cancer Prostatic Dis 25:302–305. https://doi.org/10.1038/s41391-021-00462-wCrossRefPubMed

10.

McVary KT, Holland B, Beahr JR et al (2020) Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prost Can Prost Dis 23:303–308. https://doi.org/10.1038/s41391-019-0187-5CrossRef

11.

Spinos T, Katafigiotis I, Leotsakos I et al (2023) Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature. World J Urol 41(2):413–420. https://doi.org/10.1007/s00345-022-04258-yCrossRefPubMed

12.

Bassily D, Wong V, Phillips JL et al (2021) Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. Prostate 81(14):1049–1054. https://doi.org/10.1002/pros.24201CrossRefPubMed

13.

Garden EB, Devki Shukla D, Ravivarapu KT et al (2021) Rezum therapy for patients with large prostates (≥80 g): initial clinical experience and postoperative outcomes. World J Urol 39:3041–3048. https://doi.org/10.1007/s00345-020-03548-7CrossRefPubMedPubMedCentral

14.

Parsons JK, Dahm P, Köhler TS et al (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2020. J Uro 204(4):799–804. https://doi.org/10.1007/s00345-020-03548-7CrossRef

15.

Mynderse L, Hanson D, Robb R et al (2015) Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86:122–127. https://doi.org/10.1016/j.urology.2015.03.021CrossRefPubMed

16.

Dixon C, Cedano E, Mynderse L et al (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7:13–18. https://doi.org/10.2147/RRU.S74040CrossRefPubMedPubMedCentral

17.

Tadrist A, Baboudjian M, Bah MB, et al (2023) Water vapor thermal therapy for indwelling urinary catheter removal in frail patients. Int Urol Nephrol 55(2):249–253. https://doi.org/10.1007/s11255-022-03408-w. https://pubmed.ncbi.nlm.nih.gov/36342555/

18.

Siena G, Sessa F, Cindolo L (2023) Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate Cancer Prostatic Dis 13:1–3. https://doi.org/10.1038/s41391-023-00644-8CrossRef

19.

Riedinger CB, Fantus RJ, Matulewicz RS (2019) The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. Prostate Cancer Prostatic Dis 22(2):303–308. https://doi.org/10.1038/s41391-018-0104-3CrossRefPubMed

20.

Westwood J, Geraghty R, Jones P et al (2018) Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol 10(11):327–333. https://doi.org/10.1177/1756287218793084CrossRefPubMedPubMedCentral

21.

Babar M, Labagnara K, Loloi J et al (2023) Risk factors and real-world short-term outcomes of a failed trial of void after Rezum therapy in a multiethnic population. J Endourol 37(1):67–73. https://doi.org/10.1089/end.2022.0490CrossRefPubMed

22.

Gomes CM, Nunes RV, Araujo RM et al (2008) Urodynamic evaluation of patients with lower urinary tract symptoms and small prostate volume. Urol Int 81(2):129–134. https://doi.org/10.1159/000144049CrossRefPubMed

Title: Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience
Authors: Waseem Tayeb
Raed A. Azhar
Mohnna Subahi
Sameer Munshi
Abdulrahman Qarni
Abdulaziz Bakhsh
Majid Sejiny
Turkey Almohaisen
Adel Alammari
Mohamed A. Elkoushy
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keyword: Transurethral Prostate Resection
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04739-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Ureteroplasty with buccal mucosa graft without omental wrap: an effective method to treat ureteral strictures

Letter to the editor for the article “Does the urinary microbiome profile change after treatment of bladder cancer?”

Predictors of elaborated perineal or a combined abdominoperineal approach during repair for pelvic fracture urethral injury

Follow-up of vascular-targeted photodynamic therapy in a real-world setting

Letter to the editor: “ChatGPT and most frequent urological diseases: analysing the quality of information and potential risks for patients”

Fluid absorption during flexible ureteroscopy with intelligent control of renal pelvic pressure: a randomized controlled trial